

10593018

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/008866

International filing date: 16 March 2005 (16.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/572,877  
Filing date: 19 May 2004 (19.05.2004)

Date of receipt at the International Bureau: 01 August 2005 (01.08.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1347818

UNITED STATES PATENT AND TRADEMARK OFFICE

TO ALL WHO WOULD PRESENTS SERIAL COMMERCE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*July 19, 2005*


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/572,877

FILING DATE: *May 19, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/08866

Certified by



Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label No. EV335608038US

15541 U.S.PTO  
035190460/572877  
22151 U.S.PTO

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Thaddeus C. David A.	George Basiji	Seattle, WA Seattle, WA
<input checked="" type="checkbox"/> Additional inventors are being named on the <u>one</u> separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max)		
IMAGE BASED QUANTITATION OF MOLECULAR TRANSLOCATION		
CORRESPONDENCE ADDRESS		
Direct all correspondence to:		
<input checked="" type="checkbox"/> Customer Number: 00500 OR <input type="checkbox"/> Firm or Individual Name _____ Address _____ Address _____ City _____ State _____ ZIP _____ Country _____ Telephone _____ Fax _____		
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages 25 <input type="checkbox"/> CD(s), Number _____ <input checked="" type="checkbox"/> Drawing(s) Number of Sheets 15 <input type="checkbox"/> Other (specify) _____ Fee transmittal (+copy) _____ <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. <input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees. <input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit overpayments to Deposit Account Number: 19-1090 <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		Filing Fee Amount <b>\$80.00</b>
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No. <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____		
Respectfully submitted,	 Jeffrey C. Pepe, Ph.D.	
SIGNATURE	DATE	May 19, 2004
TYPED or PRINTED NAME	REGISTRATION NO. (if appropriate)	46,985
TELEPHONE	DOCKET NUMBER:	120122.406P2

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

**PROVISIONAL APPLICATION COVER SHEET**  
**Additional Page**

PTO/SB/16 (04-04)

Approved for use through 07/31/2006. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket No.	120122.406P2
------------	--------------

**INVENTOR(S)/APPLICANT(S)**

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Keith	Frost	Seattle, WA
Brian E.	Hall	Seattle, WA
William E.	Ortyn	Bainbridge Island, WA
Michael J.	Seo	Mercer Island, WA

[Page 2 of 2]

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

483674


<b>FEE TRANSMITTAL</b> <b>for FY 2004</b>		<i>Complete If Known</i>	
<i>Patent fees are subject to annual revision.</i>		Application Number	
		Filing Date	
		First Named Inventor	<b>Thaddeus C. George</b>
		Examiner Name	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		Art Unit	
<b>TOTAL AMOUNT OF PAYMENT</b> (\$)		80.00	Attorney Docket No. <b>120122.406P2</b>

<b>METHOD OF PAYMENT</b>																																																			
<input checked="" type="checkbox"/> Payment Enclosed: <input checked="" type="checkbox"/> Check <input type="checkbox"/> Credit card <input type="checkbox"/> Money Order <input type="checkbox"/> Other																																																			
<input type="checkbox"/> Deposit Account: Deposit Account Number <b>19-1090</b> Deposit Account Name <b>Seed Intellectual Property Law Group PLLC</b>																																																			
The Director is authorized to (check all that apply) <input type="checkbox"/> Charge fee(s) indicated below <input checked="" type="checkbox"/> Credit any overpayments <input type="checkbox"/> Charge any additional fee(s) during the pendency of this application <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee <input checked="" type="checkbox"/> Charge any deficiencies to the above-identified deposit account.																																																			
<b>FEES CALCULATION</b>																																																			
<b>1. BASIC FILING FEE</b> <table border="1"> <thead> <tr> <th colspan="2">Large Entity</th> <th colspan="2">Small Entity</th> <th rowspan="2">Fee Description</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr> <td>1001</td> <td>770</td> <td>2001</td> <td>385</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>1002</td> <td>340</td> <td>2002</td> <td>170</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>1003</td> <td>530</td> <td>2003</td> <td>265</td> <td>Plant filing fee</td> <td></td> </tr> <tr> <td>1004</td> <td>770</td> <td>2004</td> <td>385</td> <td>Reissue filing fee</td> <td></td> </tr> <tr> <td>1005</td> <td>160</td> <td>2005</td> <td>80</td> <td>Provisional filing fee</td> <td></td> </tr> <tr> <td colspan="4"></td> <td><b>SUBTOTAL (1)</b></td> <td><b>(\$ 80)</b></td> </tr> </tbody> </table>						Large Entity		Small Entity		Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1001	770	2001	385	Utility filing fee		1002	340	2002	170	Design filing fee		1003	530	2003	265	Plant filing fee		1004	770	2004	385	Reissue filing fee		1005	160	2005	80	Provisional filing fee						<b>SUBTOTAL (1)</b>	<b>(\$ 80)</b>
Large Entity		Small Entity		Fee Description	Fee Paid																																														
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																
1001	770	2001	385	Utility filing fee																																															
1002	340	2002	170	Design filing fee																																															
1003	530	2003	265	Plant filing fee																																															
1004	770	2004	385	Reissue filing fee																																															
1005	160	2005	80	Provisional filing fee																																															
				<b>SUBTOTAL (1)</b>	<b>(\$ 80)</b>																																														
<b>2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE</b> <table border="1"> <thead> <tr> <th colspan="2">Large Entity</th> <th colspan="2">Small Entity</th> <th rowspan="2">Fee Description</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr> <td>1202</td> <td>18</td> <td>2202</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>1201</td> <td>86</td> <td>2201</td> <td>43</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>1203</td> <td>290</td> <td>2203</td> <td>145</td> <td>Multiple dependent claim, if not paid " Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>1204</td> <td>86</td> <td>2204</td> <td>43</td> <td>" Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> <tr> <td colspan="4"></td> <td><b>SUBTOTAL (2)</b></td> <td><b>(\$ )</b></td> </tr> </tbody> </table>						Large Entity		Small Entity		Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1202	18	2202	9	Claims in excess of 20		1201	86	2201	43	Independent claims in excess of 3		1203	290	2203	145	Multiple dependent claim, if not paid " Reissue independent claims over original patent		1204	86	2204	43	" Reissue claims in excess of 20 and over original patent						<b>SUBTOTAL (2)</b>	<b>(\$ )</b>						
Large Entity		Small Entity		Fee Description	Fee Paid																																														
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																
1202	18	2202	9	Claims in excess of 20																																															
1201	86	2201	43	Independent claims in excess of 3																																															
1203	290	2203	145	Multiple dependent claim, if not paid " Reissue independent claims over original patent																																															
1204	86	2204	43	" Reissue claims in excess of 20 and over original patent																																															
				<b>SUBTOTAL (2)</b>	<b>(\$ )</b>																																														

\*or number previously paid, if greater; For Reissues, see above

<b>FEES CALCULATION (continued)</b>																																																																																																																																																																																													
<b>3. ADDITIONAL FEES</b> <table border="1"> <thead> <tr> <th colspan="2">Large Entity</th> <th colspan="2">Small Entity</th> <th rowspan="2">Fee Description</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr> <td>1051</td> <td>130</td> <td>2051</td> <td>65</td> <td>Surcharge - late filing fee or oath</td> <td></td> </tr> <tr> <td>1052</td> <td>50</td> <td>2052</td> <td>25</td> <td>Surcharge - late provisional filing fee or cover sheet</td> <td></td> </tr> <tr> <td>1053</td> <td>130</td> <td>1053</td> <td>130</td> <td>Non-English specification</td> <td></td> </tr> <tr> <td>1812</td> <td>2520</td> <td>1812</td> <td>2520</td> <td>For filing a request for ex parte reexamination</td> <td></td> </tr> <tr> <td>1804</td> <td>920*</td> <td>1804</td> <td>920*</td> <td>Requesting publication of SIR prior to Examiner action</td> <td></td> </tr> <tr> <td>1805</td> <td>1840*</td> <td>1805</td> <td>1840*</td> <td>Requesting publication of SIR after Examiner action</td> <td></td> </tr> <tr> <td>1251</td> <td>110</td> <td>2251</td> <td>55</td> <td>Extension for reply within first month</td> <td></td> </tr> <tr> <td>1252</td> <td>420</td> <td>2252</td> <td>210</td> <td>Extension for reply within second month</td> <td></td> </tr> <tr> <td>1253</td> <td>950</td> <td>2253</td> <td>475</td> <td>Extension for reply within third month</td> <td></td> </tr> <tr> <td>1254</td> <td>1480</td> <td>2254</td> <td>740</td> <td>Extension for reply within fourth month</td> <td></td> </tr> <tr> <td>1255</td> <td>2010</td> <td>2255</td> <td>1005</td> <td>Extension for reply within fifth month</td> <td></td> </tr> <tr> <td>1401</td> <td>330</td> <td>2401</td> <td>165</td> <td>Notice of Appeal</td> <td></td> </tr> <tr> <td>1402</td> <td>330</td> <td>2402</td> <td>165</td> <td>Filing a brief in support of an appeal</td> <td></td> </tr> <tr> <td>1403</td> <td>290</td> <td>2403</td> <td>145</td> <td>Request for oral hearing</td> <td></td> </tr> <tr> <td>1451</td> <td>1510</td> <td>1451</td> <td>1510</td> <td>Petition to institute a public use proceeding</td> <td></td> </tr> <tr> <td>1452</td> <td>110</td> <td>2452</td> <td>55</td> <td>Petition to revive - unavoidable</td> <td></td> </tr> <tr> <td>1453</td> <td>1330</td> <td>2453</td> <td>665</td> <td>Petition to revive - unintentional</td> <td></td> </tr> <tr> <td>1501</td> <td>1330</td> <td>2501</td> <td>665</td> <td>Utility issue fee (or reissue)</td> <td></td> </tr> <tr> <td>1502</td> <td>480</td> <td>2502</td> <td>240</td> <td>Design issue fee</td> <td></td> </tr> <tr> <td>1503</td> <td>640</td> <td>2503</td> <td>320</td> <td>Plant issue fee</td> <td></td> </tr> <tr> <td>1460</td> <td>130</td> <td>1460</td> <td>130</td> <td>Petitions to the Commissioner</td> <td></td> </tr> <tr> <td>1807</td> <td>50</td> <td>1807</td> <td>50</td> <td>Processing fee under 37 CFR 1.17(q)</td> <td></td> </tr> <tr> <td>1806</td> <td>180</td> <td>1806</td> <td>180</td> <td>Submission of Information Disclosure Stmt</td> <td></td> </tr> <tr> <td>8021</td> <td>40</td> <td>8021</td> <td>40</td> <td>Recording each patent assignment per property (times number of properties)</td> <td></td> </tr> <tr> <td>1809</td> <td>770</td> <td>2809</td> <td>385</td> <td>Filing a submission after final rejection (37 CFR § 1.129(a))</td> <td></td> </tr> <tr> <td>1810</td> <td>770</td> <td>2810</td> <td>385</td> <td>For each additional invention to be examined (37 CFR § 1.129(b))</td> <td></td> </tr> <tr> <td>1801</td> <td>770</td> <td>2801</td> <td>385</td> <td>Request for Continued Examination (RCE)</td> <td></td> </tr> <tr> <td>1802</td> <td>900</td> <td>1802</td> <td>900</td> <td>Request for expedited examination of a design application</td> <td></td> </tr> <tr> <td colspan="4">Other fee (specify) _____</td> <td><b>SUBTOTAL (3)</b></td> <td><b>(\$ )</b></td> </tr> </tbody> </table>						Large Entity		Small Entity		Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	1051	130	2051	65	Surcharge - late filing fee or oath		1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet		1053	130	1053	130	Non-English specification		1812	2520	1812	2520	For filing a request for ex parte reexamination		1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action		1251	110	2251	55	Extension for reply within first month		1252	420	2252	210	Extension for reply within second month		1253	950	2253	475	Extension for reply within third month		1254	1480	2254	740	Extension for reply within fourth month		1255	2010	2255	1005	Extension for reply within fifth month		1401	330	2401	165	Notice of Appeal		1402	330	2402	165	Filing a brief in support of an appeal		1403	290	2403	145	Request for oral hearing		1451	1510	1451	1510	Petition to institute a public use proceeding		1452	110	2452	55	Petition to revive - unavoidable		1453	1330	2453	665	Petition to revive - unintentional		1501	1330	2501	665	Utility issue fee (or reissue)		1502	480	2502	240	Design issue fee		1503	640	2503	320	Plant issue fee		1460	130	1460	130	Petitions to the Commissioner		1807	50	1807	50	Processing fee under 37 CFR 1.17(q)		1806	180	1806	180	Submission of Information Disclosure Stmt		8021	40	8021	40	Recording each patent assignment per property (times number of properties)		1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))		1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))		1801	770	2801	385	Request for Continued Examination (RCE)		1802	900	1802	900	Request for expedited examination of a design application		Other fee (specify) _____				<b>SUBTOTAL (3)</b>	<b>(\$ )</b>
Large Entity		Small Entity		Fee Description	Fee Paid																																																																																																																																																																																								
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																										
1051	130	2051	65	Surcharge - late filing fee or oath																																																																																																																																																																																									
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet																																																																																																																																																																																									
1053	130	1053	130	Non-English specification																																																																																																																																																																																									
1812	2520	1812	2520	For filing a request for ex parte reexamination																																																																																																																																																																																									
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																																									
1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action																																																																																																																																																																																									
1251	110	2251	55	Extension for reply within first month																																																																																																																																																																																									
1252	420	2252	210	Extension for reply within second month																																																																																																																																																																																									
1253	950	2253	475	Extension for reply within third month																																																																																																																																																																																									
1254	1480	2254	740	Extension for reply within fourth month																																																																																																																																																																																									
1255	2010	2255	1005	Extension for reply within fifth month																																																																																																																																																																																									
1401	330	2401	165	Notice of Appeal																																																																																																																																																																																									
1402	330	2402	165	Filing a brief in support of an appeal																																																																																																																																																																																									
1403	290	2403	145	Request for oral hearing																																																																																																																																																																																									
1451	1510	1451	1510	Petition to institute a public use proceeding																																																																																																																																																																																									
1452	110	2452	55	Petition to revive - unavoidable																																																																																																																																																																																									
1453	1330	2453	665	Petition to revive - unintentional																																																																																																																																																																																									
1501	1330	2501	665	Utility issue fee (or reissue)																																																																																																																																																																																									
1502	480	2502	240	Design issue fee																																																																																																																																																																																									
1503	640	2503	320	Plant issue fee																																																																																																																																																																																									
1460	130	1460	130	Petitions to the Commissioner																																																																																																																																																																																									
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)																																																																																																																																																																																									
1806	180	1806	180	Submission of Information Disclosure Stmt																																																																																																																																																																																									
8021	40	8021	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																																									
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))																																																																																																																																																																																									
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))																																																																																																																																																																																									
1801	770	2801	385	Request for Continued Examination (RCE)																																																																																																																																																																																									
1802	900	1802	900	Request for expedited examination of a design application																																																																																																																																																																																									
Other fee (specify) _____				<b>SUBTOTAL (3)</b>	<b>(\$ )</b>																																																																																																																																																																																								

\*Reduced by Basic Filing Fee Paid

<b>SUBMITTED BY</b>				Customer Number
Name (Print/Type)	Jeffrey C. Pepe, Ph.D.		Registration No. Attorney/Agent	
Signature			Date	May 19, 2004

## IMAGE-BASED QUANTITATION OF MOLECULAR TRANSLOCATION

### BACKGROUND OF THE INVENTION

#### Field of the Invention

The present disclosure relates generally to methods for detecting specific molecules in cells, and more specifically, to the use of imagery in methods for quantitating the movement of molecules within a cell, including adherent and non-adherent cells, such as movement to the nucleus, or to another cellular organelle or compartment.

#### Description of the Related Art

Signal transduction pathways regulate most cellular biological processes and 10 have a critical influence on cellular responses to external stimuli. Typically, cell surface receptors that bind to a specific extracellular mediator trigger a cascade of intracellular signaling events that alter cellular metabolism or gene expression, and such changes contribute to the cellular response. The intracellular signaling cascade often involves the translocation of transcription factors or second messengers from the cytoplasm to the nucleus.

15 Historically, nuclear translocation events have been studied microscopically by observing the sub-cellular localization of fluorescent probe-labeled signaling molecules. Until recently, microscopic applications have been limited due to the subjective nature and the lack of means to quantitate imagery. Currently, several quantitative plate based microscopy platforms are available that attempt to quantitate translocation (ArrayScan, Cellomics, Inc. 20 (Pittsburgh, PA); Laser Scanning Cytometer, Compucyte Corporation (Cambridge, MA); IN Cell Analyzer, Amersham International plc. (Little Chalfont, England)). However, these microscopy platforms typically rely on the use of adherent cell lines, and their biological responses may differ from suspension-type cells (which include most blood cells).

Traditionally, the measurement of the translocation of fluorescently bound 25 molecules into the nucleus has been determined by a method referred to as the Nuc-Cyt difference (Ding *et al.*, *J. Biol. Chem.* 273:28897, 1998). This measurement involves the

following steps: (1) determining the boundaries of the nucleus which has been stained with a nuclear stain; (2) eroding the mask or area contained within the boundaries to insure the entire area is within the nucleus; (3) summing up the total fluorescence intensity associated from the labeled molecules of interest (Total Nuclear Fluorescence); (4) dilating the nuclear boundary to 5 determine an annular ring solely contained in the cytoplasm, and integrate the fluorescence associated with the labeled molecule of interest (Annular Cytoplasm Fluorescence); and (5) calculating the difference between the Total Nuclear and Annular Cytoplasm Fluorescence to yield the Nuc-Cyt difference. However, this method is unlikely to produce the best measurement because it relies on an accurate nuclear mask, subjective erosion and dilation 10 routines that determine the nuclear and cytoplasmic boundaries, an additional subjective dilation of the cytoplasm mask to create an annular volume, and both the cytoplasm and the nucleus have areas that are not represented in the calculation.

Thus, the need exists for techniques that can allow quantitation of molecular transport, such as nuclear translocation, in cells in flow to afford the opportunity to study 15 suspension-based cell lines as well as primary cells. For example, such techniques would allow detailed analysis of nuclear translocation responses in subset of cells, such as blood cells. The present invention meets such needs, and further provides other related advantage.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows staining of NF $\kappa$ B nuclear translocation in A-549 cells using 20 immunofluorescence microscopy.

Figures 2A and 2B show staining of NF $\kappa$ B nuclear translocation in A-549 cells using multispectral imaging.

Figure 2C shows staining of nuclear translocation of NF- $\kappa$ B in immune cells. The left panel shows a monocytic cell line imaged simultaneously in darkfield, green 25 fluorescence (fluorescein isothiocyanate (FITC) labeled anti-NF- $\kappa$ B), brightfield, and red fluorescence (nuclear stain 7-aminoactinomycin D). Each image row represents a different, single cell. The first cell is untreated and cells 2- 4 have been treated with lipopolysaccharide

(LPS). The right panel is a statistical analysis of the imagery that quantitatively characterizes the degree of NF- $\kappa$ B translocation to the nucleus.

Figure 3 shows quantitation of NF- $\kappa$ B nuclear translocation in A-549 cells using image correlation analysis (see Figure 3 for more detail).

5 Figure 4 shows staining of NF- $\kappa$ B nuclear translocation in THP-1 cells using immunofluorescence microscopy.

Figure 5 shows staining and quantitation of NF- $\kappa$ B nuclear translocation in THP-1 cells using multispectral imaging.

10 Figure 6 shows nuclear translocation of NF- $\kappa$ B in THP-1 cells (monocyte cell line) untreated (from left, first panel, images; second panel, quantitation of first panel images) and treated with LPS (third panel, images; fourth panel, quantitation of third panel images). Images are from darkfield, NF- $\kappa$ B labeled, brightfield, and 7-AAD nuclear label.

15 Figure 7 shows images of nuclear translocation of NF- $\kappa$ B in THP-1 cells untreated (left panel) and treated with LPS (right panel). Images include brightfield and a composite of cells stained with anti-NF- $\kappa$ B and with 7-AAD.

Figure 8 shows 7-AAD mask and NF- $\kappa$ B mask used in a compartmental correlation feature calculation.

Figure 9 shows quantitation of compartmental correlation feature in untreated and LPS-treated THP-1 cells.

20 Figures 10A and 10B show imagery of THP-1 cells (A) untreated and (B) LPS-treated, and the three populations (untranslocated – green, transitional – yellow, and translocated – red) identified in the quantitation of Figure 9.

25 Figure 11 shows images of nuclear translocation of NF- $\kappa$ B in adherent A-549 cells untreated (from left, first panel, images; second panel, quantitation of first panel images) and treated with IL-1 $\beta$ /TNF- $\alpha$  (third panel, images; fourth panel, quantitation of third panel images). Images are from darkfield, NF- $\kappa$ B labeled, brightfield, and 7-AAD nuclear label.

Figure 12 shows images of nuclear translocation of NF- $\kappa$ B in A-549 cells untreated (left panel) and treated with IL-1 $\beta$ /TNF- $\alpha$  (right panel). Images include brightfield and a composite of cells stained with anti-NF- $\kappa$ B and with 7-AAD.

Figure 13 shows quantitation of compartmental correlation feature in untreated and IL-1 $\beta$ /TNF- $\alpha$ -treated A-549 cells.

#### DETAILED DESCRIPTION

The instant disclosure relates to the use of multi-mode imagery of cells, including in non-adherent and adherent cell types, to monitor or identify molecular processes and movement in and between all cellular compartments. An advantage of the methods provided in the instant disclosure is that the shortcomings of the Nuc-Cyt difference calculation discussed above are generally obviated. Specifically, the methods of the instant disclosure use a measurement based upon statistical correlation, referred to herein as Compartmental Correlation Feature (CCF), which is a more robust method than the Nuc-Cyt calculation because (i) a single Nuclear Mask is used, (ii) spatial information is taken into account, (iii) subjective dilation, erosion, and annular dilation routines are not required, and (iv) the entire cellular nucleus is taken into account. Discussed in more detail below are single-step methods of using morphometric and photometric features from comprehensive multispectral imagery, in combination with CCF, to permit the analysis or observation of, for example, molecular movement or transport into a cell, out of a cell, within a cell, or between subcellular compartments. Thus, it should be understood that reference herein to "movement of a molecule in a cell" encompasses movement or transport of a molecule or molecules into a cell, out of a cell, within a cell, or between subcellular compartments, and combinations thereof. An exemplary image system for use with the methods in the instant disclosure is an ImageStream® 100 multispectral imaging flow cytometer platform, which produces high-resolution brightfield, darkfield, and fluorescence images with the simplified sample handling and quantitative power of flow cytometry. In addition, the IDEASTM analysis software can quantify over 200 photometric and morphometric parameters for each cell that passes through the imaging system, including parameters that can quantify the cellular and sub-cellular location of molecules, probes, and other indigenous or exogenous compounds within a cell.

In the present description, any concentration range, percentage range, ratio range, or integer range is to be understood to include the value of any integer within the recited

range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer, etc.), unless otherwise indicated. As used herein, the term "about" means  $\pm 15\%$ . As used herein, the use of an indefinite article, such as "a" or "an", should be understood to refer to the singular and the plural of a noun or noun phrase (*i.e.*, meaning "one or more" of the 5 enumerated elements or components). The use of the alternative (*e.g.*, "or") should be understood to mean either one, both or any combination thereof of the alternatives.

By way of background, methodologies for simultaneous high speed multispectral imaging in brightfield, darkfield, and four channels of fluorescence of cells in flow were recently developed (*see, e.g.*, U.S. Patent Nos. 6,211,955 and 6,249,341). U.S. 10 Patent Application No. 2002/0146734 illustrates an exemplary imaging system (*e.g.*, the ImageStream platform). Cells are hydrodynamically focused into a core stream and orthogonally illuminated for both darkfield and fluorescence imaging. The cells are simultaneously trans-illuminated via a spectrally-limited source (*e.g.*, filtered white light or a light emitting diode) for brightfield imaging. Light is collected from the cells with an imaging 15 objective lens and is projected on a charge-coupled detector (CCD). The optical system has a numeric aperture of 0.75 and the CCD pixel size in object space is 0.5 microns square, allowing high resolution imaging at event rates of approximately 100 cells per second. Each pixel is digitized with 10 bits of intensity resolution, providing a minimum dynamic range of three decades per pixel. In practice, the spread of signals over multiple pixels results in an 20 effective dynamic range that typically exceeds four decades per image. Additionally, the sensitivity of the CCD can be independently controlled for each multispectral image, resulting in a total of approximately six decades of dynamic range across all the images associated with an object.

Prior to projection on the CCD, the light is passed through a spectral 25 decomposition optical system that directs different spectral bands to different lateral positions across the detector (*see, e.g.*, U.S. Patent No. 6,249,341). With this technique, an image is optically decomposed into a set of 6 sub-images, each corresponding to a different color component and spatially isolated from the remaining sub-images. This process allows for identification and quantitation of signals within the cell by physically separating on the

detector signals that may originate from overlapping regions of the cell. Spectral decomposition also allows multimode imaging: the simultaneous detection of brightfield, darkfield, and multiple colors of fluorescence. This is exemplified in the figures of U.S. Patent Application No. 2002/0146734, which depicts a red brightfield illumination source and the 5 associated transmitted light images in the red detector channel adjacent to fluorescent and scattered light images in the other spectral channels. The process of spectral decomposition occurs during the image formation process rather than via digital image processing of a conventional composite image.

The CCD may be operated using a technique called time-delay-integration 10 (TDI), a specialized detector readout mode that preserves sensitivity and image quality even with fast relative movement between the detector and the objects being imaged. As with any CCD, image photons are converted to photocharges in an array of pixels. However, in TDI operation the photocharges are continuously shifted from pixel to pixel down the detector, parallel to the axis of flow. If the photocharge shift rate is synchronized with the velocity of 15 the flowing cell's image, the effect is similar to physically panning a camera: image streaking is avoided despite signal integration times that are orders of magnitude longer than in conventional flow cytometry. For example, an instrument may operate at a continuous data rate of approximately 30 megapixels per second and integrate signals from each object for 10 milliseconds, allowing the detection of even faint fluorescent probes within cell images that 20 are acquired at high-speed. Careful attention to pump and fluidic system design to achieve highly laminar, non-pulsatile flow eliminates any cell rotation or lateral translation on the time scale of the imaging process (see, e.g., U.S. Patent No. 6, 532,061).

A real-time algorithm analyzes every pixel read from the CCD to detect the presence of object images and calculate a number of basic morphometric and photometric 25 features, which can be used as criteria for data storage. Data files encompassing 10,000-20,000 cells are typically about 100 MB in size and, therefore, can be stored and analyzed using standard personal computers. The TDI readout process operates continuously without any "dead time", which means every cell can be imaged and the coincidental imaging of two or more cells at a time presents no barrier to data acquisition.

Such an imaging system can be employed to determine morphological, photometric, and spectral characteristics of cells and other objects by measuring optical signals, including light scatter, reflection, absorption, fluorescence, phosphorescence, luminescence, etc.

5 As used herein, "morphological parameters" may be basic (e.g., nuclear shape) or may be complex (e.g., identifying cytoplasm size as the difference between cell size and nuclear size). For example, morphological parameters may include nuclear area, perimeter, texture or spatial frequency content, centroid position, shape (i.e., round, elliptical, barbell-shaped, etc.), volume, and ratios of any of these parameters. Morphological parameters may  
10 also include cytoplasm size, texture or spatial frequency content, volume and the like, of cells. Morphological parameters may also be of other organelles (e.g., mitochondria) or for other cellular compartments (e.g., plasma membrane or organelle membrane).

As used herein, "photometric measurements" with the aforementioned imaging system can enable the determination of nuclear optical density, cytoplasm optical density, 15 background optical density, and the ratios of any of these values. An object being imaged can be stimulated into fluorescence or phosphorescence to emit light, or may be luminescent wherein light is produced without stimulation. In each case, the light from the object may be imaged on a TDI detector of the imaging system to determine the presence and amplitude of the emitted light, the number of discrete positions in a cell or other object from which the light  
20 signal(s) originate(s), the relative placement of the signal sources, and the color (wavelength or waveband) of the light emitted at each position in the object.

In using an imaging system as described herein, it should be made clear that a separate light source is not required to produce an image of the object (cell), if the object is luminescent (i.e., if the object produces light). However, many of the applications of an 25 imaging system as described herein will require that one or more light sources be used to provide light that is incident on the object being imaged. A person having ordinary skill in the art will know that the location of the light sources substantially affects the interaction of the incident light with the object and the kind of information that can be obtained from the images on a TDI detector.

In addition to imaging an object with the light that is incident on it, a light source can also be used to stimulate emission of light from the object. For example, a cell having been contacted with probe conjugated to a fluorochrome (e.g., such as FITC, PE, APC, Cy5, or Cy5.5) will fluoresce when excited by light, producing a corresponding characteristic 5 emission spectra from any excited fluorochrome probe that can be imaged on a TDI detector. Light sources may alternatively be used for causing the excitation of fluorochrome probes on an object, enabling a TDI detector to image fluorescent spots produced by the probes on the TDI detector at different locations as a result of the spectral dispersion of the light from the object that is provided by prism. The disposition of these fluorescent spots on the TDI detector 10 surface will depend upon their emission spectra and their location in the object.

Each light source may produce light, which can either be coherent, non-coherent, broadband or narrowband light, depending upon the application of the imaging system desired. Thus, a tungsten filament light source can be used for applications in which a narrowband light source is not required. For applications such as stimulating the emission of 15 fluorescence from probes, narrowband laser light is preferred, since it also enables a spectrally decomposed, non-distorted image of the object to be produced from light scattered by the object. This scattered light image will be separately resolved from the fluorescent spots produced on a TDI detector, so long as the emission spectra of any of the spots are at different wavelengths than the wavelength of the laser light. The light source can be either of the 20 continuous wave (CW) or pulsed type, preferably a pulsed laser. If a pulsed type illumination source is employed, the extended integration period associated with TDI detection can allow the integration of signal from multiple pulses. Furthermore, it is not necessary for the light to be pulsed in synchronization with the TDI detector.

The present disclosure provides methods of using both photometric and 25 morphometric features derived from multi-mode imagery of objects in flow. Such methods can be employed to analyze molecular movement within or between cells, in heterogeneous populations of cells when entrained in a fluid flowing through an imaging system. As used herein, cells may be eukaryotic or prokaryotic or viral, human, non-human animal, plant, unicellular, a primary cell culture or culture-adapted cell line, immortalized or immortalizable,

differentiated or differentiable, and the like. In addition, cells may be genetically engineered (transduced, transformed or transfected) with one or more chromosomally integrated or episomal recombinant nucleic acid sequences. The cells may have been exposed to one or more chemicals or compounds to induce or repress signaling pathways (e.g., signal 5 transduction pathway) or other cellular function. However, it should be understood that these cells and exemplary methods might be used for imaging and distinguishing other moving objects that have identifiable photometric and morphometric features, such as systems biology structures (cytomic objects), organelles, liposomes, subcellular compartments, polymeric microspheres or capsules, nanostructures, nanomolecules, and the like.

10 In the embodiments of the present invention, it is to be understood that relative movement exists between the object being imaged and the imaging system. In most cases, it will be more convenient to move the object than to move the imaging system. However, it is also contemplated that in some cases, the object may remain stationary and the imaging system move relative to it. As a further alternative, both the imaging system and the object may be in 15 motion, which movement may be in different directions and/or at different rates.

In any of the aforementioned methods, multiple images may be collected simultaneously. Furthermore, in any of the aforementioned methods, there is relative motion between the cell and the detector. In addition, in any of the aforementioned methods, the detector is a time delay integration charge-coupled detector.

## 20 COMPARTMENTAL CORRELATION FEATURE

As set forth above, the methods of the instant disclosure have been designed to overcome the shortcomings of the Nuc-Cyt difference calculation when monitoring, for example, nuclear translocation. That is, the Nuc-Cyt calculation requires, among other routines, accurate determination of a nuclear mask, subjective erosion and dilation routines that 25 determine the nuclear and cytoplasmic boundaries, and subjective dilation of the cytoplasm mask to create an annular volume. The instant disclosure provides the use of an imaging system to track or correlate the movement of a molecule in a cell using a calculation referred to as Compartmental Correlation Feature (CCF). For example, using the multispectral imaging

capabilities of an imaging system (e.g., ImageStream®), at least two different spectral images are collected corresponding to the emission wavelengths of a fluorescent dye specific for a cellular compartment (e.g., nucleus, mitochondria, cytoplasm, membrane) and a fluorescent dye specific for a translocated molecule. A cellular compartment mask may be generated 5 based on the cellular compartment stain image, then a correlation measurement is made between the cellular compartment mask and the dye area of the translocated molecule. Consequently, molecules that are translocated to the targeted cellular compartment should have a high correlation (i.e., the images should show significant overlap), whereas cells lacking cellular compartment translocation should have a low correlation (i.e., images that show less of 10 an overlap). The correlation value for each cell can be plotted as a histogram, which will display the degree of cellular compartment translocation of a molecule for a cell population. Furthermore, as noted above, the CCF can be used to determine or analyze molecular movement within any cellular compartment, such as translocation to or from the nucleus, movement to or from the cytoplasm, or movement to or from a cellular membrane, etc., and 15 combinations thereof.

Figure 2 illustrates the case of a nuclear translocation assay in which a fluorescent nucleic acid binding dye, 7-aminoactinomycin D (7-AAD, shown as red fluorescence), is used to stain the nucleus, while a different fluorescent marker (green; e.g., a FITC conjugated antibody) is used to label a translocating molecule of interest (e.g., NF-κB). 20 Using the multispectral imaging capabilities of, for example, the ImageStream®, at least two different spectral images are collected, corresponding to the emission wavelengths of the nuclear fluorescent dye and the fluorescent dye on the molecule NF-κB (to track translocation). A nuclear mask is generated from the nuclear stain image and then a correlation measurement is made between the nuclear mask area of both fluorescence 25 channels. Cells that exhibited nuclear translocation of NF-κB had a high correlation (see, e.g., Figure 2C, image rows 2-4), while cells with low nuclear translocation had a low correlation (see, e.g., Figure 2C, image row 1). The correlation value for each cell was plotted as a histogram, which displays the degree of NF-κB nuclear translocation for the cell population (see, e.g., Figure 2C, graph on right).

## COMPARTMENTAL CORRELATION FEATURE CALCULATION

Compartmental Correlation is a measurement based upon a statistical definition of correlation. The correlation of X and Y is the measurement defined by

$$\rho(X, Y) = \text{Cov}(X, Y) / (\sigma_X \sigma_Y)$$

5 in which X and Y are the fluorescent nuclear and translocating molecule images.

$\text{Cov}(X, Y)$  is the covariance of X and Y and is defined by:

$$\text{Cov}(X, Y) = \text{Expected Value of} [ (X - \mu_X)(Y - \mu_Y) ]$$

Also,  $\mu_X, \sigma_X$  and  $\mu_Y, \sigma_Y$  are the mean and standard deviations of X and Y, respectively. The

measurement  $\rho(X, Y)$  is also known as the correlation coefficient. Correlation is most effective

10 in measuring relationships between X and Y that are linear.

Similarity can be correlation, which is applied to imagery wherein X and Y are the pixel representations of imagery. First, the mask, M, is defined, wherein M is the set of coordinates (i,j). Then N can equal the number of elements in the set M. Then:

$$\mu_X = \Sigma X(i,j) / N \quad \text{and} \quad \sigma_X = \sqrt{\{\Sigma (X(i,j) - \mu_X)(X(i,j) - \mu_X)\} / (N-1)},$$

15  $\mu_Y = \Sigma Y(i,j) / N \quad \text{and} \quad \sigma_Y = \sqrt{\{\Sigma (Y(i,j) - \mu_Y)(Y(i,j) - \mu_Y)\} / (N-1)},$

$$\text{Cov}(X, Y) = \Sigma (X(i,j) - \mu_X)(Y(i,j) - \mu_Y) / (N-1)$$

When Compartmental Correlation is applied to images that exhibit molecular movement or translocation, this value tends to shift closer to a value of 1.0. When the images reveal lack of molecular movement or translocation (untranslocation), this value tends to shift 20 closer to a value of -1.0. The Compartmental Correlation measurement and the imagery indicate that the different degree of translocation of NF- $\kappa$ B into the nucleus is a linear relationship. Therefore, Compartmental Correlation is optimal for measuring such a relationship.

An exemplary embodiment of such a correlation is shown in Figure 3. In order 25 to quantitate the extent of NF- $\kappa$ B nuclear translocation in A-549 cells treated with TNF- $\alpha$  / IL-1 $\beta$ , the degree of pixel intensity between the NF- $\kappa$ B and nuclear images of cell within a

masked region of interest was analyzed. The NF- $\kappa$ B image of a cell with a high degree of translocation will look qualitatively similar to the nuclear image of that cell, resulting in a high degree of correlation between the two images. In contrast, the NF- $\kappa$ B image of a cell without any translocation will have little signal in the nuclear space, resulting in an inverse correlation with the nuclear image. Figure 3A shows the masked areas used for the correlation analysis on an untranslocated and a translocated cell. Two features were calculated, the correlation coefficient ( $\rho$ ) and, in this case, similarity is calculated as a logarithmic transformation of  $\rho$ , which features are represented by the following formula, respectively:

$$\rho(X, Y) = \text{Cov}(X, Y) / (\sigma_X \sigma_Y)$$

$$\text{Similarity} = \ln(1 + \rho) / (1 - \rho)$$

As set forth herein,  $\rho$  measures the degree to which the spatial distribution of intensities over two separate images is correlated, with a range from  $-1$  (inverse correlation) to  $+1$  (complete correlation). Here, similarity values range from  $-\infty$  to  $+\infty$ , allowing standard statistical comparisons (means and standard deviations) between groups to be made. Histogram overlays of NF- $\kappa$ B / 7-AAD correlation and similarity allows the differentiation of untreated (green) A-549 cells from TNF- $\alpha$  / IL-1 $\beta$  treated (red) A-549 cells. As described herein, the fidelity of these classifiers can be validated by inspection of the image galleries of the cells.

## MASK DETERMINATION

20 In order for the correlation between pixel intensities to provide unambiguous evidence for or against the co-location of probes (e.g., labeled molecules) in cells, an appropriate sub-set of pixels should be selected over which the correlation is to be computed. If, for example, background pixels not belonging to the cell of interest are included in the set, a strong positive correlation may be found, even when the probes tend to separate within the cell because both probes are present in larger quantities within the cell than outside the cell. In 25 general, a variety of chemical, morphological, and intensity-based methods may need to be applied in a given experiment to select the pixels of interest.

In the example of nuclear translocation, the task of selecting the pixels of interest is simplified by the presence of the nuclear probe. In this assay, the pixels of interest are those directly illuminated by the nucleus and cytoplasm. The presence of the nuclear probe means that all that is usually needed to get a sufficiently accurate set of pixels is a mask based 5 on a blurred image of the nuclear probe, perhaps extended to include regions (near the nucleus) where the nuclear probe intensity is varying sufficiently rapidly. In the case of membrane probes, certain parameters should be chosen, such as a narrow band of pixels right on the edge of the cell, while excluding from consideration those either on the interior or exterior. Morphological criteria will play a role in constructing an appropriate set of pixels in the case 10 of membranes and the morphology required is of two types. The first is a local constraint, requiring the band of pixels of increased intensity to be sufficiently narrow in order to qualify as a piece of the membrane. The second is a more global criterion, requiring that the band of pixels be sufficiently close to the global boundary defining the interior of the cell.

## USES

15 A multispectral imaging system and CCF can be used in a variety of applications, including diagnostics, drug discovery, and the like. For example, an imaging system may be used to identify compounds that affect or alter the activation of transcription factor NF- $\kappa$ B in cells of the immune system. Immune cells may be contacted with particular chemicals, cytokines, or environmental agents to examine whether translocation of the NF- $\kappa$ B 20 molecule from the cytoplasm to the nucleus occurs as part of an immune response. The quantitative measurement of the amount of NF- $\kappa$ B in the nucleus versus the cytoplasm may, therefore, be extremely useful in the development of drugs that target immune function. Conventional high content screening systems are hindered in the analysis of NF- $\kappa$ B distribution due to the difficulty of imaging non-adherent immune cells on slides or plates and 25 accurately measuring the quantity of NF- $\kappa$ B in the thin band of cytoplasm that characterize immune cells. The ImageStream platform, for example, eliminates these constraints with its ability to image non-adherent cells directly in suspension, its high resolution, and the statistical power (e.g., use of CCF) associated with its ability to analyze tens of thousands of cells.

By way of background, it is well established that Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ ) and Interleukin 1- $\beta$  (IL-1 $\beta$ ) induce translocation of NF $\kappa$ B from the cytoplasm to the nucleus in many cell types. In Figure 11, an adherent human lung carcinoma cell line A-549 was either not treated or treated for 1 hr with IL-1 $\beta$  and TNF- $\alpha$ . The cells were trypsinized 5 and washed off the plate to adapt the cells to flow, and probed for NF- $\kappa$ B (stained with anti-NF- $\kappa$ B mAb - AF488 donkey anti-mouse IgG). The nucleus was also stained with 7-AAD. Using ImageStream and the CCF, a quantifiable difference in the nuclear localization NF- $\kappa$ B was observed when comparing untreated and IL-1 $\beta$  /TNF- $\alpha$  treated cells (see Figures 11 and 13). Thus, the methods of the present disclosure may be used with adherent cells and cell 10 lines.

By way of background and wishing to be bound by theory, NF- $\kappa$ B resides predominantly in the cytoplasm in resting cells. Activating treatments (e.g., IL-1  $\beta$  /TNF- $\alpha$  or LPS) induce NF- $\kappa$ B translocation into the nucleus in responsive cell types. Thus, the ratio of nuclear to cytoplasmic NF $\kappa$ B increases with LPS treatment. Similar to the A-549 cells, NF- $\kappa$ B 15 is translocated from the cytoplasm to the nucleus when the non-adherent human monocyte cell line, THP-1, is exposed to lipopolysaccharide (LPS). Using the identical probing protocol and CCF, again a quantifiable difference in the nuclear localization NF- $\kappa$ B is demonstrated when comparing untreated and LPS-treated cells (see Figures 6 and 9). A nuclear and NF- $\kappa$ B pixel signal correlation analysis CCF was used to quantitate the difference between untranslocated 20 NF- $\kappa$ B and NF- $\kappa$ B translocated to the cell nucleus. The CCF distinguished location-specific (nuclear and cytoplasmic) quantitation of NF- $\kappa$ B to distinguish LPS-treated from untreated THP-1 cells. Thus, the methods of the present disclosure may also be used with non-adherent cells and cell lines.

#### CLASSIFIER APPROACH: COMPARTMENTAL CORRELATION FEATURE SCORING

25 The CCF is an algorithmic feature that correlates the variation of pixels (from the mean) across two channels, in this case the 7-AAD (nuclear) and NF- $\kappa$ B channels, within a generous 75% 7-AAD mask. This feature reduces cell-to-cell variation judgment calls associated with integrated nuclear to cytoplasmic NF- $\kappa$ B intensity ratios. This feature also

avoids cell-to-cell variation in the inclusion/expulsion of background-like pixels associated with user defined NK- $\kappa$ B masks (see Figures 9 and 13).

All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety. The invention having been described, the following examples are intended to illustrate, and not limit, the invention.

## EXAMPLES

### EXAMPLE 1

## INDUCTION OF TRANSLOCATION IN ADHERENT CELLS

Human lung carcinoma cell line A-549, obtained from ATCC (Rockville, MD), was maintained in RPMI 1640 (Gibco, Grand Island, NY) containing 5% fetal bovine serum, 1 mM sodium pyruvate (Mediatech, Herndon, VA), 100 µM nonessential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (BioWhittaker, Walkersville, MD) in 5% CO<sub>2</sub> atmosphere at 37°C. The density of exponentially growing cells was less than 3x10<sup>5</sup> cells per ml at the time of all treatments. To induce NF-κB translocation into the nucleus from the cytoplasm, cells were treated for 1 hr with IL-1β and TNF-α.

The following is the experimental procedure for TNF- $\alpha$ /IL-1 $\beta$  induced Nuclear Translocation of NF- $\kappa$ B in A-549 cells

### Samples:

At the end, resuspend in 100  $\mu$ l 0.1% triton X-100/PBS.

20 Unstained and NF $\kappa$ B can be mixed and run as one file, then a separate .rif of unlabeled cells can be created in IDEAS. The 7-AAD control must be run separately, because 7-AAD comes off of labeled cells and stains unlabeled cells, confounding compensation. Furthermore, we run the sample with 7-AAD in the buffer to increase staining intensity (washing it away reduces the intensity about four-fold)

25

2) Experimental samples – start with  $8 \times 10^6$  total cells for untreated and  $10^7$  for TNF/IL-1 treated. Stain according to following protocol.

A-549 cells require special handling to resuspend properly. Resuspend pellets by pipeting up and down with a pipetman until cells appear dispersed. Then vortex.

**A. Materials**

01. anti-NF $\kappa$ B (F6) : Santa Cruz Biotechnology (Cat. No.SC-8008), 200  $\mu$ g/ml
02. Alexa Fluor488 donkey anti-mouse IgG: Molecular Probes (Cat ), 1.1 mg/ml
03. Streptavidin Alexa Fluor 488: Molecular Probes
04. Recombinant human TNF- $\alpha$  : BD (Cat# 554618, Lot# 0000056653)
05. Recombinant human IL-1 $\beta$ : ebi0science (Cat# 14-8018-62, Lot#)
06. A549 cells (ATCC No. CCL-185)
- 10 07. Dulbecco's MEM
08. Fetal Calf Serum
09. F-25 Culture Flask
10. 0.25 % trypsin / EDTA
11. Phosphate buffered saline without  $\text{Ca}^{2+}/\text{Mg}^{2+}$  (PBS)
- 15 12. 4% PFA/PBS (Fixation Buffer)
13. 0.1% triton X-100/PBS (Perm Buffer)

**B. Cell preparation**

We used A549 cells cultured in Dulbecco's MEM supplemented with 10% fetal calf serum in an incubator containing 5%  $\text{CO}_2$  at 37. A-549 cells were stimulated with or 20 without TNF- $\alpha$  and IL-1 $\beta$  for 45 min to induce nuclear translocation of NF- $\kappa$ B.

01. Culture A549 cells in the T-75  $\text{cm}^2$  culture flask containing 20 ml of the 10% FCS/ Dulbecco's MEM.
02. Stimulate the exponentially growing cells with TNF- $\alpha$  (2.0 ng/ml) and IL-1 $\beta$  (10 pg/ml) for 45 min at 37°C under 5%  $\text{CO}_2$  humidified atmosphere.
- 25 03. After stimulation, discard media and wash cells with 5-10 ml of PBS.
04. Add 2 ml of 0.25 % trypsin / EDTA to cells, and incubate 37°C for 1 min or until cells have detached.
05. Suspend cells by adding 8 ml of complete DMEM.
- 30 06. transfer the cell suspension to 15 ml centrifuge tube.
07. Centrifuge at 300  $\times$  g 10' 4°C, and remove media.
08. Fix cells by resuspending @  $10^7$  cells/ml in 4% PFA/PBS 30' 4°C.
09. Wash with PBS, then perm cells by resuspending @  $2 \times 10^7$  cells/ml in 0.1% triton X-100/0.02% EDTA/PBS (Perm) 30' 4°C.
- 35 10. Add equal volume of anti-NF $\square$ B 20  $\mu$ g/mL in Perm (final mAb concentration of 10  $\mu$ g/mL) 15' 4°C.
11. Wash Perm Buffer.

12. Resuspend  $10^7$  cells/ml in Perm + AF488 donkey anti-mouse IgG (10  $\mu$ g/mL) 15' 4°C.
13. Filter 70  $\mu$ m mesh and wash with Perm.
14. Resuspend  $5 \times 10^7$  cells/ml Perm + 10  $\mu$ M 7-AAD 5' and run directly on the ImageStream.

5

## EXAMPLE 2

## INDUCTION OF TRANSLOCATION IN NON-ADHERENT CELLS

Human monocyte cell line THP-1, obtained from ATCC (Rockville, MD), were maintained in RPMI 1640 (Gibco, Grand Island, NY) containing 5% fetal bovine serum, 1 mM sodium pyruvate (Mediatech, Herndon, VA), 100  $\mu$ M nonessential amino acids, 100 U/ml penicillin, 100  $\mu$ g/ml streptomycin, and 2 mM L-glutamine (BioWhittaker, Walkersville, MD) in 5% CO<sub>2</sub> atmosphere at 37°C. The density of exponentially growing cells was less than 3x10<sup>5</sup> cells per ml at the time of all treatments. To induce NF- $\kappa$ B translocation into the nucleus from the cytoplasm, cells were treated for 1 hr with LPS.

15 The following is the experimental procedure for LPS-induced Nuclear  
Translocation of NF- $\kappa$ B in THP-1 cells

### Samples:

At the end, resuspend in 100  $\mu$ l 0.1% triton X-100/PBS.

Unstained and NF $\kappa$ B can be mixed and run as one file, then a separate .rif of unlabeled cells can be created in IDEAS. The 7-AAD control must be run separately, because 7-AAD comes off of labeled cells and stains unlabeled cells, confounding compensation. Furthermore, we run the sample with 7-AAD in the buffer to increase staining intensity (washing it away reduces the intensity about four-fold)

2) Experimental samples – start with  $10^7$  total cells for untreated LPS-treated. Stain according to following protocol.

C. Materials

- 5 14. anti-NF $\kappa$ B (F6) : Santa Cruz Biotechnology (Cat. No.SC-8008), 200  $\mu$ g/ml
- 15. Alexa Fluor488 donkey anti-mouse IgG: Molecular Probes (Cat ), 1.1 mg/ml
- 16. Streptavidin Alexa Fluor 488: Molecular Probes
- 17. Lipopolysaccharide (LPS) from E. Coli 0111B4 : Sigma (Cat# L2630, Lot# )
- 18. THP-1 cells
- 10 19. RPMI
- 20. Fetal Calf Serum
- 21. T-75 cm $^2$  Culture Flask
- 22. EDTA
- 23. Phosphate buffered saline without Ca $^{2+}$ /Mg $^{2+}$  (PBS)
- 15 24. 4% PFA/PBS (Fixation Buffer)
- 25. 0.1% triton X-100/PBS (Perm Buffer)

D. Cell preparation

We used THP-1 cells cultured in RPMI supplemented with 10% fetal calf serum in an incubator containing 5% CO $_2$  at 37. THP-1 cells were stimulated with or 20 without LPS and for 60 min to induce nuclear translocation of NF- $\kappa$ B.

- 15. Culture THP-1 cells in the T-75 cm $^2$  culture flask containing 50 ml of the 10% FCS/ RPMI ( $3 \times 10^5$  cells/mL).
- 16. Stimulate the exponentially growing cells with LPS for 60 min at 37°C under 5% CO $_2$  25 humidified atmosphere.
- 17. Centrifuge at 300 x g 10' 4°C, and remove media.
- 18. Fix cells by resuspending @  $10^7$  cells/ml in 4% PFA/PBS 30' 4°C.
- 19. Wash with PBS, then perm cells by resuspending @  $2 \times 10^7$  cells/ml in 0.1% triton X- 100/0.02% EDTA/PBS (Perm) 30' 4°C.
- 30 20. Add equal volume of anti-NF $\kappa$ B 20  $\mu$ g/mL in Perm (final mAb concentration of 10  $\mu$ g/mL) 15' 4°C.
- 21. Wash Perm Buffer.
- 22. Resuspend  $10^7$  cells/ml in Perm + AF488 donkey anti-mouse IgG (10  $\mu$ g/mL) 15' 4°C.
- 23. Filter 70  $\mu$ m mesh and wash with Perm.
- 35 24. Resuspend  $5 \times 10^7$  cells/ml Perm + 10  $\mu$ M 7-AAD 5' and run directly on ImageStream.

### EXAMPLE 3

#### NUCLEAR STAINING AND NF- $\kappa$ B STAINING

Control (untreated) cell and LPS or IL-1 $\beta$  / TNF- $\alpha$  treated cells were independently counted and washed once in phosphate buffered saline (PBS, Fair Lawn, NJ).

5 Each cell group was resuspended at  $10^7$  cells/ml in 10  $\mu$ M 7-aminoactinomycin D (7-AAD, Molecular Probes) for 10 minutes at room temperature. Cells were additionally stained with anti-NF- $\kappa$ B mAb - AF488 donkey anti-mouse IgG. Each cell group was washed, fixed in 2% paraformaldehyde (Sigma), and analyzed by flow cytometry and immunofluorescence microscopy.

10

### EXAMPLE 4

#### CONVENTIONAL FLOW CYTOMETRY AND IMAGING FLOW CYTOMETRY

For flow cytometry, cell fluorescence data excited by a 488 nm laser were acquired using the FACSort™ cytometer (BD Immunocytometry Systems, San Jose, CA) and analyzed using CellQuest™ (BD Immunocytometry Systems). For imaging flow cytometry, 15 fixed cells at  $5 \times 10^7$  cells per ml were run at 100 cells per second on an ImageStream100™ ("Beta" version), and the data analyzed using the ImageStream Data Analysis and Exploration Software™ (IDEASTM).

### EXAMPLE 5

#### INSTRUMENTATION FOR MULTISPECTRAL IMAGING FLOW CYTOMETRY

20 Figures in U.S. Patent Application No. 2002/0146734 provide an exemplary layout of the ImageStream™ platform. Cells are hydrodynamically focused into a core stream and orthogonally illuminated for both darkfield and fluorescence imaging. The cells are simultaneously trans-illuminated via a spectrally-limited source (e.g., filtered white light or a light emitting diode) for brightfield imaging. Light is collected from the cells with an imaging 25 objective lens and is projected on a charge-coupled detector (CCD). The optical system has a numeric aperture of 0.75 and the CCD pixel size in object space is 0.5 microns square,

allowing high resolution imaging at event rates of approximately 100 cells per second. Each pixel is digitized with 10 bits of intensity resolution, providing a minimum dynamic range of three decades per pixel. In practice, the spread of signals over multiple pixels results in an effective dynamic range that typically exceeds four decades per image. Additionally, the 5 sensitivity of the CCD can be independently controlled for each multispectral image, resulting in a total of approximately six decades of dynamic range across all the images associated with an object.

Prior to projection on the CCD, the light is passed through a spectral decomposition optical system that directs different spectral bands to different lateral positions 10 across the detector (see, e.g., U.S. Patent No. 6,249,341). With this technique, an image is optically decomposed into a set of 6 sub-images, each corresponding to a different color component and spatially isolated from the remaining sub-images. This is exemplified in U.S. Patent Application No. 2002/0146734, which depicts a red brightfield illumination source and the associated transmitted light images in the red detector channel adjacent to fluorescent and 15 scattered light images in the other spectral channels. The process of spectral decomposition occurs during the image formation process rather than via digital image processing of a conventional composite image.

The CCD is operated using time-delay-integration (TDI), in which image photons converted to photocharges in an array of pixels are continuously shifted (at a rate 20 synchronized with the velocity of the flowing cell's image) from pixel to pixel down the detector and parallel to the axis of flow to avoid image streaking. For example, the instrument can operate at a continuous data rate of approximately 30 megapixels per second and integrate signal from each object for 10 milliseconds, which allows the detection of even faint 25 fluorescent probes within cell images that are acquired at high speed. Attention to pump and fluidic system design to achieve highly laminar, non-pulsatile flow can eliminate cell rotation or lateral translation on the time scale of the imaging process (see, e.g., U.S. Patent No. 6, 532,061). Every pixel read from the CCD is analyzed by a real-time algorithm that detects the presence of object images and calculates a number of basic morphometric and photometric features, which can be used as criteria for data storage. Data files encompassing

10,000-20,000 cells can be about 100 MB in size, and are stored and analyzed using standard personal computers.

#### EXAMPLE 6

##### IMMUNOFLUORESCENCE MICROSCOPY

5        Fixed control and treated cells were placed on a conventional glass slide (Erie Scientific, Portsmouth, NH), mixed 1:1 with Antifade (Molecular Probes) and covered with a cover slip. The cells were visualized at 400X using an Eclipse E600 (Nikon, Melville, NY) fluorescence microscope equipped with filters appropriate for Alexa Fluor 488 (535/40 nm emission) and 7-AAD (630/60 nm emission).

10        From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

## CLAIMS

1. A method for measuring molecular movement in a cell, comprising contacting a cell with a compartment marker and with a molecular marker, imaging the marked cell with a detector, creating a compartment mask, and correlate said compartment mask and said molecular marker to measure molecular movement in a cell.
2. The method of claim 1 wherein there is relative motion between the cell and the detector.
3. The method of claim 1 wherein the molecular marker is a fluorescent labeled antibody.
4. The method of claim 1 wherein the compartment marker is a fluorescent molecule.
5. The method of claim 1 wherein the compartment is nucleus, cytoplasm, or membrane.
6. The method of claim 1 wherein the molecule marked is NF- $\kappa$ B.
7. The method of claim 1 further comprising the step of inducing molecular movement in the cell.
8. The method of claim 7 wherein the induced molecular movement is nuclear translocation.
9. The method of claim 7 wherein the molecular movement is induced with LPS or IL-1 $\beta$  / TNF- $\alpha$ .

10. A method for measuring nuclear translocation in a cell, comprising contacting a cell with a nuclear marker and with a molecular marker, imaging the marked cell with a detector, creating a nuclear mask, and correlate said nuclear mask and said molecular marker to measure molecular movement in a cell.

11. The method of claim 10 wherein there is relative motion between the cell and the detector.

12. The method of claim 10 further comprising the step of inducing molecular movement in the cell.

13. The method of claim 12 wherein the induced molecular movement is nuclear translocation.

14. The method of claim 12 wherein the molecular movement is induced with LPS or IL-1 $\beta$ / TNF- $\alpha$ .

15. The method of claim 10 wherein the nuclear marker is 7-AAD.

16. The method of claim 10 wherein the molecule marked is NF- $\kappa$ B.

17. The method according to any one of claims 1-16 wherein the images are collected simultaneously.

18. The method according to any one of claims 1-16 wherein the detector is a time delay integration charge-coupled detector.

## ABSTRACT OF THE DISCLOSURE

**The use of an imaging system, cell compartment markers, and molecular markers in methods for correlating the movement of molecules within a cell to a particular compartment are provided, including measuring and correlating molecule movement in adherent and non-adherent cells.**

120122.406P2 / 483629

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
-  BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Docket No. 120122.406P2  
Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US




**Figure 1: Visualization of NFκB Nuclear Translocation in A549 Cells Using Immunofluorescence Microscopy**

TNF- $\alpha$  and IL-1 $\beta$  stimulation initiates a signaling cascade that results in the translocation of NFκB from the cytoplasm to the nucleus of the adherent human carcinoma cell line A549 cells. Untreated A549 cells (a) and A549 cells treated with TNF- $\alpha$  (2 ng/ml) and IL-1 $\beta$  (10 pg/ml) for 1 hour (b) were trypsinized and probed for NFκB expression and nuclear morphology. Briefly, the cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% triton, and incubated with mouse anti-NFκB (p65) + Alexa Fluor<sup>®</sup> 488 donkey anti-mouse IgG. Cells were washed and resuspended in 1% paraformaldehyde containing 7-AAD, then mixed with an equal volume of antifade and visualized on slides using a Nikon Eclipse E600 fluorescence microscope equipped with bandpass filters appropriate for FITC (535/40 nm) and 7-AAD (630/60 nm) fluorescence. NFκB images in grey are depicted on the left. NFκB (green) / 7-AAD (red) composite images on the right demonstrate the nuclear localization of NFκB following TNF- $\alpha$  / IL-1 $\beta$  treatment.


*Fig. 1*

Docket No. 120122.406P2  
Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US



**Fig. 2**

Docket No. 120122.406P2  
Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US




**Figure 2C. NF-κB Nuclear Translocation in Immune Cells**


The data (above left) show cells imaged simultaneously in darkfield, green fluorescence, brightfield, and red fluorescence. The sample consisted of a monocytic cell line stained with an antibody against the NF-κB transcription factor (green) as well as a nuclear stain (red). Cells treated with lipo-polysaccharide (image rows 2-4) exhibit translocation of NF-κB from the cytoplasm to the nucleus while untreated cells lack NF-κB in the nuclear compartment (top row). A statistical analysis of imagery from 6616 cells quantitatively characterizes the degree of NF-κB nuclear translocation in the sample. Amnis' ImageStream platform is the only cell analysis technology that can perform this valuable assay on immune cells in suspension.

**Fig. 2C**

Docket No. 120122.406P2  
 Inventor(s): Thaddeus C. George *et al.*  
 Express Mail No. EV335608038US




**Fig. 3**



**Figure 4: Visualization of NFκB Nuclear Translocation in THP-1 Cells Using Immunofluorescence Microscopy**

LPS stimulation initiates a signaling cascade that results in the translocation of NFκB from the cytoplasm to the nucleus of the non-adherent human monocyte cell line THP-1. Untreated THP-1 cells (a) and THP-1 cells treated with LPS (100 ng/ml) for 1 hour (b) were probed for NFκB expression and nuclear morphology. Briefly, the cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% triton, and incubated with mouse anti-NFκB (p65) + Alexa Fluor® 488 donkey anti-mouse IgG. Cells were washed and resuspended in 1% paraformaldehyde containing 7-AAD, then mixed with an equal volume of antifade and visualized on slides using a Nikon Eclipse E600 fluorescence microscope equipped with bandpass filters appropriate for FITC (535/40 nm) and 7-AAD (630/60 nm) fluorescence. Note the relatively thin band of cytoplasm in the untranslocated NFκB images characteristic of this monocytic cell line.

***Fig. 4***



**Figure 5: Visualization and Quantitation NF-κB Nuclear Translocation in THP-1 Cells Using ImageStream Multispectral Imaging**

Untreated (a) and LPS treated (b) THP-1 cells were prepared as described in Figure 4 and imaged in flow using the ImageStream 100 platform. Plotting NF-κB / 7-AAD Similicity vs. NF-κB Peak Intensity revealed a range of cells based on similarity that were gated into three populations. Each gated population has an associated image gallery that can be visually inspected. The image galleries have display the NF-κB image adjacent to a composite image (green NF-κB / red 7-AAD) for each object within a given population. Morphologic inspection of the image galleries revealed that NF-κB had translocated to the nucleus in High Similicity but not Low Similicity cells. Medium Similicity cells had a diffuse NF-κB staining pattern. Untreated and translocated cells had significantly different Similicity values (untreated:  $-1.36 \pm 0.04$  and  $2.68 \pm 0.35$ , respectively; LPS treated:  $0.76 \pm 0.04$  and  $3.35 \pm 0.48$ , respectively). Treatment with LPS significantly increased the percentage of NF-κB-translocated (9.71%, median similitiy value  $2.93 \pm 0.35$  to 44.6%, median similitiy value  $3.35 \pm 0.48$ ) and Medium Similicity (3.6% to 27.0%) cells.

**Fig. 5**

Docket No. 120122.406P2  
Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US




Fig. 6

Docket No. 120122.406P2

Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US






Fig. 7

Docket No. 120122.406P2  
Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US

**Object 8:**



**7-AAD stain**




**NF $\kappa$ B stain**



Feature	Value	Definition
3_Peak Intensity	571	Peak Intensity M3 2
Nuclear Plus Similarity	-0.155	Similarity Normalized UM5 2 4
Similarity 85 Cytoplasm	0.5003	Similarity Normalized UM3 2 4

**Fig. 8**

COMPARTMENTAL CORRELATION FEATURE:



Median Compartmental Correlation Feature:

Untranslocated =  $-0.5966 \pm 0.2141$


Difference of  $1.5252$

Translocated =  $0.9286 \pm 0.0423$

*Fig. 9*


Docket No. 120122.406P2  
 Inventor(s): Thaddeus C. George *et al.*  
 Express Mail No. EV335608038US

Docket No. 120122.406P2  
 Inventor(s): Thaddeus C. George *et al.*  
 Express Mail No. EV335608038US



**Fig. 10A**

Docket No. 120122.406P2  
 Inventor(s): Thaddeus C. George *et al.*  
 Express Mail No. EV335608038US



**Fig. 10B**




Fig. 11

Docket No. 120122.406P2  
Inventor(s): Thaddeus C. George *et al.*  
Express Mail No. EV335608038US






Fig. 12

Compartmental Correlation Feature: A-549 Cells

Untreated



IL-1 $\beta$ /TNF- $\alpha$ -Treated






Median Compartmental Correlation Feature:  
 $-2815 +/- 0.2806$

Difference of  $1.1826$

*Fig. 13*

$0.9011 +/- 0.1255$



**APPLICATION DATA SHEET**

**Application Information**

**Application number::**

**Filing Date::**

**Application Type::**

Provisional

**Subject Matter::**

Utility

**Suggested classification::**

**Suggested Group Art Unit::**

**CD-ROM or CD-R?::**

None

**Number of CD disks::**

**Number of copies of CDs::**

**Sequence submission?::**

**Computer Readable Form (CRF)?::**

No

**Number of copies of CRF::**

**Title ::**

IMAGE BASED QUANTITATION OF  
MOLECULAR TRANSLOCATION

**Attorney Docket Number::**

120122.406P2

**Request for Early Publication?::**

No

**Request for Non-Publication?::**

No

**Suggested Drawing Figure::**

**Total Drawing Sheets::**

15

**Small Entity?::**

Yes

**Petition included?::**

No

**Petition Type::**

**Licensed U.S. Gov't Agency::**

**Contract or Grant No::**

**Secrecy Order in Parent Appl.?::**

No

**First Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	
Status::	Full capacity
Given Name::	Thaddeus
Middle Name::	C.
Family Name::	George
Name Suffix::	
City of Residence::	Seattle
State or Province of Residence::	WA
Country of Residence::	US
Street of mailing address::	1712 NW 63rd Street
City of mailing address::	Seattle
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98107

**Second Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	
Status::	Full capacity
Given Name::	David
Middle Name::	A.
Family Name::	Basiji
Name Suffix::	
City of Residence::	Seattle
State or Province of Residence::	WA
Country of Residence::	US
Street of mailing address::	6538 Greenwood Avenue N
City of mailing address::	Seattle
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98103

**Third Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	
Status::	Full capacity
Given Name::	Keith
Middle Name::	
Family Name::	Frost
Name Suffix::	
City of Residence::	Seattle
State or Province of Residence::	WA
Country of Residence::	US
Street of mailing address::	4801B South Roxbury Street
City of mailing address::	Seattle
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98118

**Fourth Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	
Status::	Full capacity
Given Name::	Brian
Middle Name::	E.
Family Name::	Hall
Name Suffix::	
City of Residence::	Seattle
State or Province of Residence::	WA
Country of Residence::	US
Street of mailing address::	1121 17th Avenue, Apt. A
City of mailing address::	Seattle
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98122

**Fifth Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	
Status::	Full capacity
Given Name::	William
Middle Name::	E.
Family Name::	Ortyn
Name Suffix::	
City of Residence::	Bainbridge Island
State or Province of Residence::	WA
Country of Residence::	US
Street of mailing address::	11546 Matsu Place NE
City of mailing address::	Bainbridge Island
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98110

**Sixth Applicant Information**

Applicant Authority Type::	Inventor
Primary Citizenship Country::	
Status::	Full capacity
Given Name::	Michael
Middle Name::	J.
Family Name::	Seo
Name Suffix::	
City of Residence::	Mercer Island
State or Province of Residence::	WA
Country of Residence::	US
Street of mailing address::	8120 SE 77th Place
City of mailing address::	Mercer Island
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98040

**Correspondence Information**

Correspondence Customer Number :: **00500**

**Representative Information**

Representative Customer Number::		<b>00500</b>
----------------------------------	--	--------------

**Domestic Priority Information**

Application ::	Continuity Type::	Parent Application::	Parent Filing Date::

**Foreign Priority Information**

Country::	Application number::	Filing Date::	Priority Claimed::

**Assignee Information**

Assignee name::	Amnis Corporation
Street of mailing address::	2505 Third Avenue, Suite 210
City of mailing address::	Seattle
State or Province of mailing address::	WA
Country of mailing address::	US
Postal or Zip Code of mailing address::	98121